Texas Pharmacy Recalls Compounded Glutathione Injection Nationwide After Elevated Endotoxin Levels

A compounded injectable widely marketed through wellness, longevity and IV-therapy channels is the subject of a fresh safety recall. On August 5, 2026, Victory Medical Center Pharmacy of Austin, Texas announced a voluntary nationwide recall, to the patient level, of three lots of its Compounded Glutathione 200 mg/mL multi-dose vials after the pharmacy's own testing identified elevated bacterial endotoxin levels. Because compounded glutathione is frequently prescribed and shipped to patients through telehealth and med-spa channels, the recall is relevant to anyone who obtained an injectable glutathione product from these lots.

What was recalled

The recall covers Victory Medical Center Pharmacy's VMC Compounded Glutathione 200 mg/mL supplied in multi-dose vials. According to the FDA recall notice, the affected lot numbers are 1980571, 1981940 and 1984345, each carrying an expiration date of August 27, 2026. The recall is described as voluntary and nationwide, conducted to the patient level, meaning the pharmacy is seeking return of product already dispensed to individual patients rather than only pulling stock from distributors.

The notice states the product was distributed to patients in Texas, Florida and New York. Patients who have any vial from the listed lots are directed to stop using it and to contact the pharmacy.

Why it was recalled

The stated reason is that pharmacy testing identified elevated bacterial endotoxin levels in the affected product. Endotoxins are components of certain bacteria that can trigger a strong inflammatory response when introduced into the bloodstream, even when no live organisms are present. Per the FDA notice, there is a reasonable probability that injectable products with elevated endotoxin levels could cause significant medical events including fevers, hypotension, inflammatory reactions, anaphylactic shock and death. That is the stated risk profile for elevated-endotoxin injectables generally, as described in the recall; it is not a claim that every exposed patient will experience harm.

Reported adverse events

The pharmacy says that, to date, it has received reports of adverse events associated with the product. The reported effects listed in the notice include fever, chills, severe headache, nausea, vomiting, tachycardia (a racing heartbeat), changes in blood pressure, body aches and instances of injection site reactions. These are reports received by the pharmacy rather than confirmed, adjudicated case counts, and the notice does not state how many patients were affected or the severity of individual cases.

A recurring concern with compounded glutathione injectables

This is not the first time the FDA has flagged compounded glutathione for injection. In a June 2019 communication, the agency highlighted concerns about using the dietary ingredient glutathione to compound sterile injectable drugs. In that action, FDA testing found glutathione samples containing excessive bacterial endotoxin, with some results reported as high as five times the appropriate limit, and the agency noted it had received reports of eight patients who experienced reactions after receiving glutathione injections. The FDA's broader point was that an ingredient marketed for use in dietary supplements may not be suitable for sterile injectable compounding, because ingredients not intended for that use can carry impurities and contaminants.

The 2026 Victory Medical Center recall is a separate, pharmacy-initiated action rather than a new FDA enforcement step, but it sits against that longer backdrop: sterile injectable compounding depends on ingredient quality and rigorous testing, and endotoxin is one of the specific failure modes regulators have repeatedly cited for this product category.

Why this matters for telehealth patients

Injectable glutathione is commonly marketed as an antioxidant or skin-brightening product and is frequently prescribed through telehealth wellness clinics, longevity practices and IV-therapy providers, then shipped directly to patients. That distribution model means an affected patient may not have a local pharmacist to consult and may be several steps removed from the compounding pharmacy that prepared the product. A patient-level recall for a mailed injectable therefore depends on the pharmacy reaching each recipient. Victory Medical Center Pharmacy says it is notifying its prescribers and patients by telephone and mail and is arranging for retrieval and proper disposition of the recalled product.

What affected patients can do

This is general information, not medical advice. If you have an injectable glutathione product, these steps follow the guidance in the recall notice and standard FDA reporting channels:

• Check whether your vial is VMC Compounded Glutathione 200 mg/mL from lot 1980571, 1981940 or 1984345 (expiration August 27, 2026), and stop using it if so.
• Contact Victory Medical Center Pharmacy at (512) 279-0985 for questions about the recall and for return of affected product.
• If you have used an affected lot and feel unwell, contact your prescribing clinician or seek medical care; the notice describes potential reactions ranging from fever and chills to more serious events.
• Report any adverse event to the FDA's MedWatch program online or by calling 1-800-332-1088.
• Ask any telehealth or compounding provider how they source and test injectable products, including whether each batch is tested for bacterial endotoxin.